Clinical Trial

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a randomized, open-label, active controlled, multi-center, phase 3 clinical study to compare the efficacy and safety of Mitoxantrone Hydrochloride Liposome Injection with Chidamide in patients with relapsed/refractory Peripheral T Cell Lymphoma (PTCL).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2020-12-11.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-05-27
Trial Details
NCT Number NCT04668690
Lead Sponsor CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions Peripheral T Cell Lymphoma
Enrollment 193 participants
Start Date 2021-04-13
Primary Completion 2027-12-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-31